September 2018 post

9/17/2018 8:00:00 AM

The 2018 congress of the European Society of Cardiology (ESC), recently concluded, has re-affirmed the exceptional status of this globe-spanning scientific endeavour. Society sources report that over five days, delegates from more than 150 countries presented, discussed or attended 4,500 abstracts in 500 expert sessions covering 400 cardiology topics. A total of 92 late breaking science studies were presented including 17 Late Breaking Clinical Trials, six Clinical Trial Updates, and 20 Registries: these are extraordinary numbers.

Exceptional also is the calibre of the materials now being brought into the public domain. In the arena of acute heart failure the VERDICT trial produced the perhaps surprising but undoubtedly important finding that very early diagnosis and treatment in patients with non-ST segment elevation acute coronary syndrome was not superior to a strategy of assessment deferral: postponing invasive examination and treatment for up to 72 hours appears to be successful as a very early approach.

In parallel with these mainstream activities, the practical tutorials lectures that I trailed in my August post were a great success, with high rates of attendance. In three full days, a faculty of 17 acknowledged experts dealt purposefully and informatively with major themes relating to the use of inodilators, particularly levosimendan, in acute and advanced heart failure. All the presentations, including the Q&A sessions which followed all lectures, were recorded and may be viewed freely at www.acuteHF.com.